1. The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases
   Luca Antonioli et al, 2019, Pharmacological Reviews CrossRef
2. Current and future biomarkers in allergic asthma
   U. M. Zissler et al, 2016, Allergy CrossRef
3. IL-4 prevents adenosine-mediated immunoregulation by inhibiting CD39 expression
   Fengqin Fang et al, 2022, JCI Insight CrossRef
4. Implications of CD39 in immune-related diseases
   Jianrui Zeng et al, 2020, International Immunopharmacology CrossRef
5. Decreased expression of ectonucleotidase E‐NPP1 in leukocytes from subjects with severe asthma exacerbation
   L. M. Montaño et al, 2016, Allergy CrossRef
6. Impaired P2X1 Receptor–Mediated Adhesion in Eosinophils from Asthmatic Patients
   Adam Wright et al, 2016, The Journal of Immunology CrossRef
7. Discriminative expression of CD39 and CD73 in Cerebrospinal fluid of patients with Multiple Sclerosis and Neuro-Behçet’s disease
   Khadija Bahrini et al, 2020, Cytokine CrossRef
8. The Cell Research Trends of Asthma: A Stem Frequency Analysis of the Literature
   Wenchao Tang et al, 2018, Journal of Healthcare Engineering CrossRef
9. Long-lived regulatory T cells generated during severe bronchiolitis in infancy influence later progression to asthma
   Jason P. Lynch et al, 2020, Mucosal Immunology CrossRef
10. Reducing Lung ATP Levels and Alleviating Asthmatic Airway Inflammation through Adeno-Associated Viral Vector-Mediated CD39 Expression
    Yung-An Huang et al, 2021, Biomedicines CrossRef